Dose-dependent pharmacokinetics and cancer chemotherapy Garth PowisMatthew M. AmesJohn S. Kovach Reviews Pages: 1 - 9
Antitumor activity of 3′, 5′-diesters of 5-fluoro-2′-deoxyuridine against murine leukemia L1210 cells Fumihiko KanzawaAkio HoshiTakeo Kawaguchi Original Articles Pages: 19 - 23
Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration Mervyn IsraelAbraham M. KarkowskyVinod K. Khetarpal Original Articles Pages: 25 - 30
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea (FIVB) in colon cancer Geoffrey FalksonJèndré C. Falkson Original Articles Pages: 31 - 34
Clinical pharmacology of oral thioguanine in acute myelogenous leukemia L. W. BroxL. BirkettA. Belch Original Articles Pages: 35 - 38
Structure-pharmacokinetic relationships for misonidazole analogues in mice Paul WorkmanJ. Martin Brown Original Articles Pages: 39 - 49
Pharmacology of amygdalin (laetrile) in cancer patients Matthew M. AmesThomas P. MoyerJoseph Rubin Original Articles Pages: 51 - 57
Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy N. ChristophidisW. J. LouisF. J. E. Vajda Original Articles Pages: 59 - 64
Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia Christer PaulMagnus BjörkholmGunnar Öberg Original Articles Pages: 65 - 73
Phase I clinical trial and pharmacology of 2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine (metoprine) (DDMP) and folinic acid (CF) Robert de JagerDaniel DupontGaston Lagrange Original Articles Pages: 75 - 80
Phase II clinical trial of DDMP (2,4-diamino-5-(3′,4′-dichlorophenyl)-6-methylpyrimidine) and folinic acid (CF) in solid tumors Robert de JagerAntonio BrugarolasEORTC Early Clinical Trials Group Original Articles Pages: 81 - 84
The pharmacokinetics of prednimustine and chlorambucil in the rat D. R. NewellC. R. ShepherdK. R. Harrap Original Articles Pages: 85 - 91
Does color of an antitumor agent predict for clinical antitumor activity? Daniel D. Von HoffJohn KuhnGary Clark Original Articles Pages: 93 - 94
Cisplatin disposition in children and adolescents with cancer William R. CromWilliam E. EvansGary C. Yee Original Articles Pages: 95 - 99
